|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | RANKL/RANK control Brca1 mutation-driven mammary tumors显示文摘 | Verena Sig Kwadwo Owusu-Boaitey Puma A Joshi Anoop Kavirayani Gerald Wimsberger Maria Novatchkova Ivona Kozieradzki Daniel Schramek Nnamdi Edokobi Jerome Hersl Aishia Sampson Ashley Odai-Afotey Conxi Lazaro Eva Gonzalez-Suarez Miguel A Pujaaa for CIMBA Holger Heyn Enrique Vidal Jennifer Cru. ickshank Hal Berman Renu Sarao Melita Tieevic Iris Uribesalgo Luigi Tortola Shuan Rao Yen Tan Georg Pfeiler Eva YHP Lee Zsuzsanna Bago-Horvath Lukas Kenner Helmuth Popper Christian Singer Rama Khokha LaundeRe P Jones Josef M Penninger | 2016 | Cell Research2016，26，7： | 3 |
| 2 | 重组脊髓灰质炎病毒用于治疗复发胶质母细胞瘤(英文)显示文摘Background The prognosis of patients with recurrent World Health Organization(WHO)grade IV malignant glioma is dismal,and there is currently no effective therapy.We conducted a dose-finding and toxicity study in this population of patients,evaluating convection-enhanced,intratumoral delivery of the recombinant nonpathogenic polio-rhinovirus chimera(PVSRIPO).PVSRIPO recognizes the poliovirus receptor CD155,which is widely expressed in neoplastic cells of solid tumors and in major components of the tumor microenvironment.Methods We enrolled consecutive adult patients who had recurrent supratentorial WHO grade IV malignant glioma,confirmed on histopathological testing,with measurable disease(contrast-enhancing tumor of≥1 cm and≤5.5 cm in the greatest dimension).The study evaluated seven doses,ranging between 107 and 1010 50%tissue-culture infectious doses(TCID50),first in a dose-escalation phase and then in a dose-expansion phase.Results From May 2012 through May 2017,a total of 61 patients were enrolled and received a dose of PVSRIPO.Dose level-1(5.0×107TCID50)was identified as the phase 2 dose.One dose-limiting toxic effect was observed;a patient in whom dose level 5(1010TCID50)was administered had a grade 4 intracranial hemorrhage immediately after the catheter was removed.To mitigate locoregional inflammation of the infused tumor with prolonged glucocorticoid use,dose level 5 was deescalated to reach the phase 2 dose.In the dose-expansion phase,19%of the patients had a PVSRIPO-related adverse event of grade 3 or higher.Overall survival among the patients who received PVSRIPO reached a plateau of 21%(95%confidence interval,11 to 33)at 24 months that was sustained at 36 months.Conclusions Intratumoral infusion of PVSRIPO in patients with recurrent WHO grade IV malignant glioma confirmed the absence of neurovirulent potential.The survival rate among patients who receivedPVSRIPO immunotherapy was higher at 24 and 36 months than the rate among historical controls. | Desjardins A Gromeier M Herndon JE 2nd Beaubier N Bolognesi DP Friedman AH Friedman HS McSherry F Muscat AM Nair S Peters KB Randazzo D Sampson JH Vlahovic G Harrison WT McLendon RE Ashley D Bigner DD | 2018 | 中华神经外科疾病研究杂志2018，17，4： | 2 |
| 3 | Esophageal Subepithelial Fibrosis in Children With Eosinophilic Esophagitis显示文摘 | Mirna Chehade Hugh A Sampson Raffaella A Morotti Margret S Magid | 2007 | Journal of Pediatric Gastroenterology and Nutrition2007，，3： | 2 |
| 4 | Long-term changes in arch form after orthodontic treatment and retention显示文摘 | De-la-Cruz A Sampson P Little RM et ol | 1995 | Am J Orthod Dentofacial Orthop1995，107，5： | 1 |
| 5 | Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant 显示文摘 | Willner P Towell A Sampson D | 1987 | Psychopharmacology1987，93，3： | 1 |
| 6 | Sarcoplasmic calcium-binding protein is an EF-hand–type protein identified as a new shrimp allergen显示文摘 | Rosalía Ayuso Galina Grishina María Dolores Ibá?ez Carlos Blanco Teresa Carrillo Ramon Bencharitiwong Silvia Sánchez Anna Nowak-Wegrzyn Hugh A. Sampson | 2009 | The Journal of Allergy and Clinical Immunology2009，，1： | 1 |
| 7 | Why we need service logic:a comparative review显示文摘 | SAMPSON S E MENOR L J BONE S A | 2010 | Journal of Applied Management and Entrepreneurship2010，，15： | 1 |
| 8 | Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network Symposium显示文摘 | Sampson HA Munoz-Furlong A Campbell RL | 2006 | J Allergy Clin Immuno12006，117，2： | 1 |
| 9 | Metastatic or embolic endometriosis, due to the menstrual dissemination of endometrial tissue into the venous circu- lation显示文摘 | SAMPSON J A | 1927 | Am J Pathol1927，3，2： | 1 |
| 10 | Real-time dispersion compensation in scanning interferometry显示文摘 | SMITH E D J ZVYAGIN A V SAMPSON D D | 2002 | Opt Lett2002，27，22： | 1 |
| 11 | Action of costal and crural parts of the diaphragm on the rib cage in dog显示文摘 | De Troyer A Sampson M Sigrist S | 1982 | J Appl Physiol1982，53，1： | 1 |
| 12 | Comparative mechanisms and rates of free radical scavenging by carotenoid antioxidants显示文摘 | Mortensen A Skibsted LH Sampson J | 1997 | FEBS Lett1997，418，12： | 1 |
| 13 | Anaphlactic reactions after gamma globulin admi nistration in patients with hypogammaglobulinaemia显示文摘 | BURKS A W SAMPSON H A BUCKLEY R H | 1986 | N Engl J Med1986，314，： | 1 |
| 14 | An operational statisti- cal typhoon intensity prediction scheme for the western north paeifie显示文摘 | Knaff J A Sampson C R DeMaria M | 2005 | Wea Forecasting2005，20，： | 1 |
| 15 | Reduction of sucrose preference by chronic unpredictable mild stress,and its restoration by a tricyclic antidepressant显示文摘 | Willner P Towell A Sampson D | | 0，，： | 1 |
| 16 | Further fatalities caused by anaphylactic reactions to food, 2001-2006显示文摘 | Boek S A Munoz Furlong A Sampson H A | 2007 | Aller- gy Clin Immunol2007，119，4： | 1 |
| 17 | Peritoneal endometriosis due to menstrual dissemination of endometrial tissue into the peritoneal cavity 显示文摘 | Sampson J A | 1927 | Am J Obstet Gynecol1927，14，： | 1 |
| 18 | Comparison of leaf area index estimates from tree allometrics and measured light interception显示文摘 | Smith F W Sampson D A Long J N | 1991 | Forest Science1991，37，6： | 1 |
| 19 | Fatalities due tosnaphylactic reactions to foods 显示文摘 | Bock S A Munoz Furlong A Sampson H A | 2001 | Allergy Clin Immunol2001，107，1： | 1 |
| 20 | Leukotrience modifiers in the treatment of asthma 显示文摘 | Sampson A Holgate S | 1998 | BMJ1998，316，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员